Nanotechnology and Oncology: Workshop Summary (2011)
Chapter: Acronyms
Acronyms
| α-CD20 |
anti-CD20, CD20 is cluster of differentiation 20, a cell surface protein |
| α-CD33 |
anti-CD33, CD33 is cluster of differentiation 33 |
| ADME |
absorption, distribution, metabolism, excretion |
| Apo-A1 |
apolipoprotein A1 |
| ASTM |
organization formerly known as the American Society for Testing and Materials |
| βhCG |
β subunit of human chorionic gonadotropin |
| BNP |
brain natriuretic peptide |
| CAS |
Chinese Academy of Sciences |
| CBEN |
Center for Biological and Environmental Nanotechnology |
| CCNE |
Center of Cancer Nanotechnology Excellence |
| CEN |
European Committee for Standardization |
| CFU-GM |
colony-forming unit granulocyte macrophage |
| CK-MB |
creatine kinase MB fraction (the MB fraction is most specific to cardiac muscle) |
| CLIO-Cy5.5 |
cross-linked iron oxide Cy5.5 (Cy5.5 is a type of cyanine fluorescent dye) |
| DARPA |
Defense Advanced Research Projects Agency |
| DEAL |
DNA-encoded antibody barcode |
| DFMO |
difluoromethylornithine |
| DNA |
deoxyribonucleic acid |
| DOX-OXD dextran conjugated doxorubicin | |
| Doxorubicin-cBR96 |
doxorubicin conjugated to chimeric |
| (α-CD174) |
monoclonal antibody cBR96 (anti-CD174, CD174 is cluster of differentiation 174, a cell surface protein) |
| DTA-IL2 |
fusion fusion protein of diphtheria toxin fragment A |
| protein (α-CD25) |
and interleukin 2 (this fusion protein targets CD25, a cell surface protein) |
| EGCG |
epigallocatechin-3-gallate |
| EGF |
epidermal growth factor |
| EGFR |
epidermal growth factor receptor |
| ELISA |
enzyme-linked immunosorbent assay |
| EMEA |
European Medicines Agency |
| EPA |
Environmental Protection Agency |
| EUFETS |
a European contract manufacturer for cell and gene therapy |
| FDA |
Food and Drug Administration |
| Genexol-PM |
Genexol–polymeric micelle |
| GFP |
green fluorescent protein |
| GM-CSF |
granulocyte-macrophage colony stimulating factor |
| GMP |
good manufacturing practices |
| gp60 |
60 kDa glycoprotein, an albumin binding protein |
| hCG |
human chorionic gonadotrophin |
| HER2 |
human epidermal growth factor receptor 2 |
| Hg |
mercury |
| IBBC |
integrated blood barcode chip |
| ICH |
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use |
| ICON |
International Council on Nanotechnology |
| IFN-γ |
interferon-γ |
| IL-1α |
interleukin-1α |
| IL-1β |
interleukin-1β |
| IL-2 |
interleukin-2 |
| IL-6 |
interleukin-6 |
| IL-10 |
interleukin-10 |
| IL-12 |
interleukin-12 |
| IND |
Investigational New Drug Application |
| IOM |
Institute of Medicine |
| ISO |
International Organization for Standardization |
| IV |
intravenous |
| KS |
Kaposi sarcoma |
| LD50 |
median lethal dose |
| LE-SN38 |
liposome-encapsulated 7-Ethyl-10-hydroxy-camptothecin |
| LErafAON |
liposome encapsulated c-raf antisense oligonucleotide |
| LMWP |
low molecular weight peptide |
| MALDI TOF MS |
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry |
| MCP-1 |
monocyte chemotactic protein-1 |
| MFNP |
magneto/fluorescent nanoparticles |
| MIT |
Massachusetts Institute of Technology |
| MR |
magnetic resonance |
| MRI |
magnetic resonance imaging |
| MTX-HSA |
human serum albumin–bound methotrexate nab nanoparticle albumin-bound |
| NCI |
National Cancer Institute |
| NCL |
Nanotechnology Characterization Laboratory |
| NIH |
National Institutes of Health |
| NIST |
National Institute of Standards and Technology |
| NK911 |
polymeric micelle carrier system for doxorubicin |
| NMR |
nuclear magnetic resonance |
| NNI |
National Nanotechnology Initiative |
| NSAIDs |
non-steroidal anti-inflammatory drugs |
| NSFC |
National Natural Science Foundation of China |
| OECD |
Organisation for Economic Co-operation and Development |
| Onco-TCS |
Onco-transmembrane carrier system, the drug vincristine |
| OSHA |
Occupational Health and Safety Administration |
| OSI-211 |
liposomal lurtotecan drug manufactured by |
| OSI |
Pharmaceuticals |
| P13K |
phosphatidylinositol 3-kinase |
| PEG |
polyethylene glycol |
| PEG-IFNα2a/-IFNα2b |
pegylated interferon α-2a/interferon α-2b |
| PEG-L-asparaginase |
polyethylene glycol conjugated asparaginase |
| PGA-paclitaxel |
polyglutamic acid conjugated paclitaxel |
| PHPMA-doxorubicin |
poly(2-hydroxypropyl methacrylate) conjugated doxorubicin |
| PK |
pharmacokinetics |
| PK1 |
N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin |
| PK2 |
N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer backbone and pendant doxorubicin (DOX) linked via a Gly-Phe-Leu-Gly peptide spacer |
| PLD-E1A |
pegylated liposomal doxorubicin–linked E1A (an adenoviral oncogene) plasmid DNA |
| PLGA |
polylactic-co-glycolic acid |
|
particle replication in non-wetting templates |
|
| PSA |
prostate specific antigen |
| RBC |
red blood cell |
| RES |
reticuloendothelial system |
| RNA |
ribonucleic acid |
| RNAi |
RNA interference |
| SGN-15 |
cBR96-doxorubicin immunoconjugate, SGN stands for Seattle Genetics Inc. |
| siRNA |
short interfering RNA or silencing RNA |
| SPARC |
secreted protein, acidic and rich in cysteine |
| SPI-77 |
sterically stabilised liposomal cisplatin |
| TGF-β |
transforming growth factor β |
| TNF |
tumor necrosis factor |
| TNF-γ |
tumor necrosis factor γ |
| UK |
United Kingdom |
| WBC |
white blood cell |
